Comparative Pharmacology
Head-to-head clinical analysis: ENDEP versus JANIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDEP versus JANIMINE.
ENDEP vs JANIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Increases synaptic concentrations of serotonin and norepinephrine by inhibiting their reuptake in the central nervous system.
Imipramine inhibits the reuptake of norepinephrine and serotonin at nerve terminals, potentiating their neurotransmission. It also has anticholinergic and antihistaminergic effects.
Initial 75 mg/day orally in divided doses, increased gradually to 150-200 mg/day; maintenance 50-150 mg/day as single dose at bedtime or in divided doses.
25-50 mg orally 2-4 times daily; maintenance 150 mg/day divided
None Documented
None Documented
Terminal elimination half-life: 15-40 hours (mean ~24 h); clinical context: steady-state achieved in 5-7 days; prolonged in elderly and CYP2D6 poor metabolizers.
5-15 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for steady state.
Renal: 70-80% as metabolites (including glucuronides, unchanged drug <5%); Biliary/Fecal: 20-30%.
Primarily renal (70-80% as metabolites, 5% unchanged); biliary/fecal (20-30% as metabolites).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant